These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11199809)

  • 1. Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
    Baas H
    J Neurol; 2000 Sep; 247 Suppl 4():IV/12-6. PubMed ID: 11199809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H; Fuchs G; Gemende I; Hueber R; Lachenmayer L; Schneider E; Schoenberger B; Werner M
    J Neurol; 2002 Oct; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
    Jenner P
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
    Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B
    Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of L-dopa-induced dyskinesias.
    Bédard PJ; Blanchet PJ; Lévesque D; Soghomonian JJ; Grondin R; Morissette M; Goulet M; Calon F; Falardeau P; Gomez-Mancilla B; Doucet JP; Robertson GS; DiPaolo T
    Mov Disord; 1999; 14 Suppl 1():4-8. PubMed ID: 10493397
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
    Metman LV; Konitsiotis S; Chase TN
    Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
    Rascol O
    J Neurol; 2000 Apr; 247 Suppl 2():II51-7. PubMed ID: 10991666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of L-dopa-induced abnormal involuntary movements.
    Agid Y; Bonnet AM; Ruberg M; Javoy-Agid F
    Psychopharmacology Suppl; 1985; 2():145-59. PubMed ID: 2987904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptors and L-dopa-induced dyskinesia.
    Berthet A; Bezard E
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S8-12. PubMed ID: 20123563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
    Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.